BluePrint Research Group, a leader in life sciences launch strategy, commercial analytics, and market research, has been acquired by Trinity Life Sciences, a life sciences commercialization strategic advisory, data analytics, and technology firm backed by Parthenon Capital Partners.
- The acquisition positions the combined company as the premier global partner for commercially focused strategy, insights, and analytics for the life sciences industry
- The combined company services clients across large pharma (including all of the Top 20), biotech, and medical
About BluePrint Research Group
BluePrint was founded in 2008 by three senior professionals with 25 years of combined industry experience in firms such as Bristol Myers Squibb, Schering Plough & Vertex. BluePrint consults with healthcare companies to inform global brand commercialization efforts for the industry’s most innovative therapies and products, impacting and improving global health and wellness.
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors.
Transaction Details
-
SectorsHealthcare & Life Sciences TechnologiesTech-Enabled & IT Services
-
ServiceM&A
-
OwnershipFounder-Owned
-
Practices
Healthcare & Life Sciences Technology
Managed IT Services
-
MPG Transaction LeaderJonathan AdlerRohan Khanna